Skip to main content

Advertisement

SpringerLink
Log in

A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation

  • Case Report
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease characterized by elevated pulmonary vascular resistance, which results in right-heart failure. We present a case of interferon (IFN)-α-induced PAH developed after living donor liver transplantation. Although IFN is categorized as a “possible” risk factor for PAH in the current international classification, it is still under recognized. Moreover, the prognosis of IFN-induced PAH is poor in the limited number of published cases. In our case, we achieved good outcome by the withdrawal of IFN and administration of combination therapy using tadalafil, beraprost, and treprostinil. Since IFN is an important treatment option in current medical therapy, its contribution to the pathogenesis of PAH should be taken into consideration. In conclusion, our case suggests the importance of PAH screening in patients treated with IFN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351:1655–1665

    Article  CAS  PubMed  Google Scholar 

  2. Amano H, Toyoda S, Arikawa T, Inami S, Otani N, Nishi Y, Kitagawa Y, Taguchi I, Abe S, Inoue T (2013) Left ventricular function in pulmonary hypertension. Heart Vessels 28(4):505–509

    Article  PubMed  Google Scholar 

  3. George MG, Schieb LJ, Ayala C, Talwalkar A, Levant S (2014) Pulmonary hypertension surveillance: United States, 2001–2010. Chest 146(2):476–495

    Article  PubMed  PubMed Central  Google Scholar 

  4. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–D41

    Article  PubMed  Google Scholar 

  5. Savale L, Sattler C, Günther S, Montani D, Chaumais MC, Perrin S, Jaïs X, Seferian A, Jovan R, Bulifon S, Parent F, Simonneau G, Humbert M, Sitbon O (2014) Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 44(6):1627–1634

    Article  CAS  PubMed  Google Scholar 

  6. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135(1):44–53

    Article  CAS  PubMed  Google Scholar 

  7. Erol MK, Erol S, Koruk M, Ertek M, Bozkurt E (2004) Effects of interferon-alpha therapy on cardiac function in patients with chronic hepatitis B infection. Heart Vessels 19(6):263–266

    Article  PubMed  Google Scholar 

  8. Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH (2010) Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 55(6):1785–1790

    Article  PubMed  PubMed Central  Google Scholar 

  9. Fruehauf S, Steiger S, Topaly J, Ho AD (2001) Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia. Ann Hematol 80(5):308–310

    Article  CAS  PubMed  Google Scholar 

  10. George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR, Mitchell JA (2012) Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ 2(4):501–504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. George PM, Oliver E, Dorfmuller P, Dubois OD, Reed DM, Kirkby NS, Mohamed NA, Perros F, Antigny F, Fadel E, Schreiber BE, Holmes AM, Southwood M, Hagan G, Wort SJ, Bartlett N, Morrell NW, Coghlan JG, Humbert M, Zhao L, Mitchell JA (2014) Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 114(4):677–688

    Article  CAS  PubMed  Google Scholar 

  12. Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM (2011) Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 30(9):982–989

    Article  PubMed  Google Scholar 

  13. Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, White RJ, TRUST Study Group (2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 29(2):137–149

    Article  PubMed  Google Scholar 

  14. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, Barst RJ (2006) Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129(3):683–688

    Article  CAS  PubMed  Google Scholar 

  15. Hatano M, Yamada H, Fukuda K, Yoshioka K, Funauchi M, Kuwana M, Sata M, Taniguchi M, Nakanishi N, Saito T, Saji T, Sasayama S (2014) Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension. Heart Vessels. doi:10.1007/s00380-014-0544-1

    PubMed  Google Scholar 

Download references

Conflict of interest

Masaru Hatano has a potential conflict of interest with GlaxoSmithKline Pharmaceutical and NIPPON SHINYAKU, which consists of lecture fees. The other authors have no potential conflicts of interest existing with any companies/organizations whose products or services may be discussed in this article.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan

    Toshiyuki Ko, Masaru Hatano, Daisuke Nitta, Hironori Muraoka, Shun Minatsuki, Teruhiko Imamura, Toshiro Inaba, Hisataka Maki, Atsushi Yao, Koichiro Kinugawa & Issei Komuro

Authors
  1. Toshiyuki Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaru Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daisuke Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hironori Muraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shun Minatsuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Teruhiko Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshiro Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hisataka Maki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Atsushi Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Koichiro Kinugawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Issei Komuro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaru Hatano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ko, T., Hatano, M., Nitta, D. et al. A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation. Heart Vessels 31, 1206–1208 (2016). https://doi.org/10.1007/s00380-015-0701-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-015-0701-1

Keywords

Search

Navigation